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ABSTRACT
Purpose: Caffeine shows wide interindividual pharmacokinetic (PK) variation, and 
therapeutic drug monitoring (TDM) may be needed. The PK profile of caffeine in 
Korean preterm neonates was investigated, and factors influencing the clearance of 
caffeine were analyzed.
Methods: Fifty-nine preterm neonates receiving caffeine for apnea of prematurity 
were enrolled in the study (gestational age, 29.5±2.2 weeks and birth weight [BW], 
1,318±358 g). Caffeine (20 mg/kg) was intravenously administered to each neonate 
as a loading dose, followed by a maintenance dose of 5-10 mg/kg/d. A total of 190 se-
rum concentrations were measured for population PK analysis and modeling using 
nonlinear mixed-effects model (NONMEM®) software.
Results: The mean serum concentration of caffeine was 15.4±4.5 mg/L (range 7.8-
33.0 mg/L). High serum concentrations (>20 mg/L) were noted in 36 samples (29%). 
At the first measurement of serum caffeine, the mean postmenstrual age was 33.9±2.3 
weeks, mean BW was 1,802±471 g, mean duration of treatment was 7.4±9.4 days, and 
mean sampling time after the last dose was 21.8±2.1 hours. In the population PK 
analysis, the clearance was 0.033 L/h and volume of distribution was 0.371 L. Typi-
cal clearance was calculated as 0.0293×(BW/70)1.33. Among the subjects receiving 5 
mg/kg/d caffeine, the most significant risk factor associated with high serum con-
centrations (>20 mg/L) was low BW (P=0.024).
Conclusion: BW was the only covariate that influenced caffeine clearance in preterm 
neonates. Preterm neonates with low BW should be carefully monitored for apnea 
and adverse reactions in addition to undergoing TDM.
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INTRODUCTION
Caffeine is a methylxanthine that acts as a nonspecific inhibitor of adenosine receptors 
and is used to wean patients from ventilatory support or as a treatment for apnea1). Pre-
mature neonates receive a loading dose of 20-80 mg/kg in the initial 30 minutes, followed 
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by a maintenance dose of 5-20 mg/kg/d 24 hours later2,3). 
The therapeutic dose range is 8-20 µg/mL, with toxic effects 
occurring at doses exceeding 20 µg/mL4). Caffeine in teracts with 
drugs metabolized by the cytochrome P450 (CYP) 1A2 enzyme 
and is eliminated by renal excretion4). Therefore, caffeine 
pharmacokinetics (PK) may vary in neonates.
The PK profile of caffeine in neonates is characterized by a 
volume of distribution of 0.8-0.9 L/kg, which is larger than that 
of children or adults4,5). In addition, the half-life of caffeine in 
neonates is approximately 72-96 hours, which is longer than 
that of adults, and is further prolonged with decreased renal 
function. The kidney is the main pathway of caffeine clearance 
in neonates; thus, newborns have lower clearance rates than 
children or adults. The population PK data on neonates, espe-
cially premature neonates, have been reported for Chinese, 
Malaysian, and Caucasian populations; however, no population 
PK data on Koreans have been analyzed. 
There are relatively fewer reports of the adverse effects of caffe-
ine than there are for other drugs used for apnea treatment. Ir-
ritability, restlessness, jitteriness, and tachycardia can occur owing 
to central nervous system (CNS) and cardiovascular stimula-
tion6-8). An increase in the caffeine levels in the body in creases 
its potency and toxicity accordingly9). Therefore, when caffeine is 
administered to premature neonates with unstable metabolism, 
therapeutic drug monitoring (TDM) is indispensable. This study 
analyzes the population PK, including serum concentration in 
preterm neonates who received caffeine for apnea of prematurity, 
and the factors affecting serum caffeine levels.
MATERIALS AND METHODS
1. Patients
The data were obtained retrospectively from medical records 
and routine caffeine monitoring of 57 hospitalized neonates 
(34 female and 23 male neonates) in the neonatal intensive 
care unit of Severance Children’s Hospital from December 2012 
to July 2013, using 190 caffeine measurements. The covariate 
data collected for each patient included sex, birth weight (BW), 
current weight, birth height, gestational age (GA), postnatal age, 
postconceptional age, ventilator care, oxygen care, and Apgar 
score. 
The accurate dosing history including date, dose, and route 
of administration was collected. The typical loading and main-
tenance doses of caffeine citrate administered intravenously 
were 20 and 5 mg/kg once daily, respectively. However, because 
of the clinical condition of the neonates, the maintenance caffe-
ine dose ranged from 5 to 10 mg/kg once daily. The exclusion 
criteria were major congenital abnormalities, blood culture-
proven sepsis, major neurological conditions, liver or renal 
disorders, or term neonates. The study protocol was approved 
by the Institutional Review Board of Yonsei University Severance 
Hospital. The requirement for informed consent was waived 
because the study was conducted retrospectively.
2. Serum sampling and analysis
Actual sampling and treatment times were recorded by a nurse 
on a data sheet and were checked independently. The serum 
caffeine concentrations were assayed by chromatography/
mass spectrometry (MS) using an API 4000TM liquid chromato-
graphy-tandem MS (LC-MS/MS) system (Applied Biosystems, 
Foster City, CA, USA). The working assay range was 0.2-50 mg/
L, and the inaccuracy and between-day and within-day variance 
were <10% across this range. Samples containing >20 mg/L 
caffeine were diluted in drug-free serum and re-assayed.
3. PK model
The concentration time course of caffeine was described 
using a one-compartment model with either zero- or first-order 
(infusion vs. oral) absorption and first-order elimination, assum-
ing a permanent non-steady-state condition. The modeling 
was performed using non-linear mixed-effects model software 
(NONMEM, version 5.1.1, Globomax LLC, Hanover, MD, USA). 
The influence of mean-centered covariates was evaluated by 
adding these to the base model, and in turn, noting the changes 
in the objective function value (OFV). The inclusion of a covariate 
was considered to have improved the fit of the data to the model 
if there was a decrease in the OFV. The differences between a pair 
of OFV values when a covariate was included (full model) and 
excluded (nested reduced model) were tested for significance 
(a=0.01) using the χ2 statistic with 1 degree of freedom.
4. Statistical analysis 
The continuous variables were presented as means±standard 
deviation (SD) and were compared using Student’s t-test. The 
categorical variables were presented as percentages and fre-
quencies and compared using the chi-square or Fisher’s exact 
test. The risk factors were analyzed using multivariable linear 
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regression analysis adjusted for GA and BW to estimate the odds 
ratios (ORs) with 95% confidence intervals (CIs). A P<0.05 was 
considered statistically significant. 
RESULTS
The patient characteristics are described in Table 1. The results 
of blood chemistry at the time of caffeine level measurement 
showed parameters within normal limits as follows. The blood 
urea nitrogen (BUN) was 7.1±5.4 mg/dL; creatinine, 0.4±0.3 
mg/dL; aspartate transaminase (AST), 28.1±29.0 IU/L; alanine 
transaminase (ALT), 14.8±21.5 IU/L; albumin, 3.2±0.3 g/dL; and 
the C-reactive protein was 1.8±3.8 mg/L (Table 2). The mean 
caffeine con centration was 15.4±5.0 mg/L, and the distribution of 
se rum caffeine levels is shown in Figure 1, with different shapes 
depicting data for different therapeutic doses. The sample analysis 
that showed toxicity potential (with serum caffeine levels >20 
mg/L) indicated that 6 (4.5%), 7 (41.2%), and 23 (60.5%) of such 
samples were associated with 5, 7.5, and 10 mg/kg maintenance 
doses, respectively. When analyzing samples with serum caffeine 
levels <20 mg/L, 129 (95.5%), 10 (58.8%), and 15 (39.5%) samples 
were associated with 5, 7.5, and 10 mg/kg maintenance doses, 
respectively. The overall drug concentration depended on the 
dose administered, but varied within the same dose. 
In the case of the 5 mg/kg administration group, the 6 and 129 
samples with serum caffeine levels >20 and <20 mg/L (high and 
normal concentration groups), respectively, were compared. 
The average BWs in the normal and high concentration groups 
were 1,784±466 g and 1,350±332 g, respectively, which differed 
significantly (P=0.026, Table 3). No significant differences were 
observed in GA (28.9 and 28.8 weeks for normal and high con-
centration groups, respectively, P=0.876, Table 3), postnatal age, 
birth weight, and Apgar score. In the univariate and multiple 
linear regression analyses (Table 4), the BW was a significant 
parameter (P=0.024), whereas the GA, postconceptional age, and 
Apgar score were not significant. The PK parameters determined 
were clearance (0.033 L/h), the volume of distribution (0.371 L), 
Table 1. Characteristics of Study Patients
Characteristic Mean±SD Range
Number of Patients, n 57
Male, n 23 
Gestational age (wks) 29.49±2.22 24.4-33.6
Postconceptional age (wks) 33.94±2.28 27.6-39.3
Postnatal age (d) 36±23 5-89
Birth weight (g) 1,318±358 530-2,210
Current weight (g) 1,802±471 770-2,995
Birth height (cm) 38.93±3.56 29.5-44
Apgar score - 1 min 4.05±1.19 2-7
Apgar score - 5 min 6.12±1.33 3-10
Ventilator care (d) 18.14±23.10 3-10
Oxygen care (d) 42.97±30.32 1-133
Number of Samples, n 190
Sample time after medication (h) 21.8±2.1 12-24
Caffeine dose (mg/kg) 6.2±2.0
5 mg/kg, n (%) 135 (71%)
7.5 mg/kg, n (%) 17 (9%)
10 mg/kg, n (%) 38 (20%)
Plus minus values are mean±SD.   
Figure 1. The distribution of serum caffeine levels at the days after 
1st dose is shown with different shapes depicting data of differ ent 
therapeutic doses.
Table 2. Laboratory Data
  Mean±SD         Range
BUN (mg/dL) 7.1±5.4 1.0-35.0
Creatinine (mg/dL) 0.4±0.3 0.2-3.2
AST (IU/L) 28.1±29.0 11-377
ALT (IU/L) 14.8±21.5 2-258
Albumin (g/dL) 3.2±0.3 2.3-4.0
CRP (mg/L) 1.8±3.8 0.3-27.4
Normal range of CRP is 0-8 mg/L.
Abbreviations: BUN, blood urea nitrogen; AST, aspartate transaminase; 
ALT, alanine transaminase; CRP, C-reactive protein. 
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apnea in premature neonates1,10). However, limited data on 
caffeine PK parameters and dosage schedules in premature 
neonates are available. The population approach is an effective 
way to determine the safety and efficacy of caffeine, but has not 
been previously applied to Korean neonates. This study is the 
first to investigate the population PK of caffeine in Korean pre-
term neonates.
The clearance and half-life of caffeine change rapidly in the 
postnatal period, and it may be necessary to adjust dosage re-
gimens as neonates grow older. Controversies exist among vari-
ous neonatal intensive care units in terms of dosage regimen, 
time of initiation, duration of therapy, and value of TDM. One 
recommended regimen reduces the dosage interval from once 
daily for neonates younger than a month to every 12, 8, or 6 hours 
for infants aged 1 to 2 months, 2 to 4 months, or 4 months and 
older, respectively11). In a previous study, the recommended 
loading dose of caffeine citrate was 20 mg/kg and the main-
tenance treatment (5 to 10 mg/kg once a day) should be admini-
stered orally or by intravenous infusion. In this study, the dosage 
interval was not adjusted based on postnatal age. Instead, a 
loading dose of 20 mg/kg caffeine was administered, followed 
by a maintenance dose of 5 mg/kg administered every 24 hours, 
and increased to 10 mg/kg based on the symptoms and serum 
caffeine levels.
Caffeine is metabolized in the liver by CYP1A212). The me-
tabolism of caffeine is limited in neonates because of their 
immature hepatic enzyme system; approximately 86% of caf-
feine dose is excreted unchanged in the urine13,14). Therefore, 
physiological variables related to renal function would influ-
ence caffeine clearance in newborns. Several other factors in-
cluding genetic variation in hepatic metabolic enzymes and 
caffeine receptors may also contribute to the variability in 
pharmacodynamic responses15-17). This study included neonates 
with normal AST, ALT, BUN, and creatinine levels, and excluded 
newborns with kidney or liver disease.
The serum concentration of caffeine should be monitored 
periodically, especially in critically ill neonates with unexplained 
adverse effects, and the therapeutic range is 8-20 mg/L18,19). In a 
study of neonates with GA of 27.6 weeks, groups that maintained 
caffeine dosing at 5 and 20 mg/kg had a mean serum caffeine 
concentration of 14.7 µg/mL (4.8-25.1 µg/mL) and 47.4 µg/mL 
(18.9-79.8 µg/mL), respectively2). In another study, the mean 
serum caffeine levels of 75 preterm neonates were 11.8 µg/
mL (4.75-26.1 µg/mL), with less than 4% >20 µg/mL20). In this 
and half-life (22.6 h). Based on these results, a clearance formula 
for each population was obtained using the following formula: 
typical clearance=0.0293×(BW/70)1.33. The clearance was signi-
ficantly correlated with the current weight, and the model was 
fitted with an OFV of 885.53 (Table 4).
DISCUSSION
For over 20 years, caffeine has been successfully used to treat 
Table 3. Comparison of Patient Characteristics between Nor-
mal and High Concentration Group
Normal group
 (N=129)
High group
 (N=6)
P-value
Gestational age (wks) 28.9±2.3 28.8±2.1 0.876
Postconceptional age (wks) 33.9±2.3 32.3±0.9 0.099
Birth weight (g) 1,212±366 1,298±363 0.575
Body weight (g) 1,784±466 1,350±332 0.026
Postnatal age (d) 35.1±23.9 25.0±12.9 0.308
Apgar score – 1 min 3.89±1.38 4.83±0.41 0.098
Apgar score – 5 min 6.00±1.34 6.67±0.82 0.230
Ventilator care 22.9±29.0 34.3±34.7 0.318
Oxygen support 49.0±30.0 37.0±6.7 0.331
Measurement after n dose 15.9±25.1 12.3±4.4 0.729
BUN (mg/dL) 7.1±5.8 10.8±11.9 0.148
Creatinine (mg/dL) 0.37±0.28 0.74±1.21 0.019
AST (IU/L) 28.8±34.0 32.0±10.9 0.817
Albumin (g/dL) 3.14±0.59 3.22±0.25 0.748
CRP (mg/L) (normal 0-8) 2.08±4.32 0.48±0.19 0.368
Data are expressed Mean±SD. 
Normal range of CRP is 0-8 mg/L.
Abbreviations: BUN, blood urea nitrogen; AST, aspartate transami-
nase; CRP, C-reactive protein.
Table 4. Multiple Linear Regression Analysis
            Beta P-value
Gestational age (wks) 2.495 0.149
Postconceptional age (wks) -2.946 0.093
Body weight (g) -0.371 0.024
Apgar score – 1min -0.015 0.885
BUN (mg/dL) -0.139 0.286
Creatinine (mg/dL) 0.123 0.322
Albumin (g/dL) -0.206 0.026
CRP (mg/L) -0.026 0.769
F= 2.794, P-value= 0.008. 
Abbreviations: BUN, blood urea nitrogen; CRP, C-reactive protein.
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study, based on neonates at 29.5 weeks GA, the mean serum 
concentration was 15.48 µg/mL (7.8-33.0 µg/mL). Among the 
neonates receiving maintenance caffeine doses of 5 and 10 mg/
kg, 6 (3%) and 23 (12%) showed serum caffeine levels >20 µg/
mL. The blood concentration of caffeine varies, and careful 
monitoring for toxicity is required. The serum concentration of 
caffeine tends to be high in underweight neonates, and extra 
caution is required with this population.
Caffeine toxicity has not been reported at the therapeutic 
plasma concentrations required to treat apnea of prematurity. 
Caffeine is a CNS and cardiovascular stimulant and has been 
associated with irritability, restlessness, jitteriness, tachycardia, 
and other cardiovascular effects4). Other side effects are feeding 
intolerance, increased urine output, and necrotizing entero-
colitis21). 
Serum caffeine levels >50 µg/mL have been associated with 
fever, tachypnea, hypertonia, vomiting, hyperglycemia, elevated 
BUN, leukocytosis, seizures, and other symptoms4,22). In another 
study, the heart rate and caffeine serum concentrations were 
significantly correlated (P<0.05), which is consistent with the 
increased probability of tachycardia with increased caffeine 
serum concentration23). TDM monitoring should be considered 
in critically ill neonates with unexplained adverse effects such 
as tachycardia therefore it has been done in our institution and 
since the highest serum caffeine concentration was 33 µg/mL 
in our study, it was not possible to assess side effects at levels 
greater than 50 µg/mL. In this study, no definite adverse effects 
were found. Moreover, no cases of serum caffeine levels >50 µg/
mL were recorded, and with constant observation, the dosage 
proved to be safe.
It is widely known that drug disposition in premature neonates 
can differ markedly from that in older children and adults19,24). 
The half-life of caffeine in preterm neonates (<33 weeks GA) 
was 87 hours, compared to 72-96 hours in the term neonate 
group20). The elimination of caffeine was severely suppressed 
in premature neonates but increased nonlinearly after birth up 
to 6 weeks of age, and reached adult values at approximately 60 
weeks postmenstrual age2). The caffeine half-life observed for 
neonates in this study was shorter than that reported in other 
studies, which may have been caused by differences in the 
postnatal days.
Individual estimates of clearance were obtained using the 
population estimates and a post hoc Bayesian analysis of 
the individual concentration measurements. The mean cl-
earance estimate was 1.8 mL/h/kg, which was lower than the 
average clearance values (7.9-8.9 mL/h/kg) reported by other 
studies20,25,26). The estimate of the population mean volume of 
distribution of caffeine (748 mL/kg) is similar to values report-
ed by other studies (911 mL/kg)2,27). For estimation of the 
parameters in the preterm neonate population, the NONMEM 
program was used to assess the PK profile information for 
caffeine. The assessment showed that postnatal age, regardless 
of current weight, was the continual variable that yielded the 
best adjustment of data in a clearance model. Thomson et al.27) 
modeled clearance as a simple function of current weight and 
postnatal age without the effect of any other covariate. Based on 
the analysis of the population PK of premature Korean neonates, 
the caffeine clearance was proven to be affected by current BW, 
in accordance with previous results. Using the proportional error 
model for the random effects parameters, this study showed an 
OFV of 885.53. The interindividual variability of clearance was 
14.87%, and the residual variability was 18.44%. Moreover, the 
estimated values for the final parameters presented a typical 
pattern with a precision within acceptable limits for both the fixed 
and random effects parameters (<20 and <50%, respectively)28). 
The limitations of this study are the small sample size and 
insufficient variation in sampling times. In addition, the study 
was retrospectively conducted, and the toxicity symptoms could 
not be verified. 
A comparison of the PK data of Koreans with that of other 
ethnicities revealed similarities in the clearance and volume of 
distribution values. The neonates had lower BWs than normal, 
which may have increased the caffeine serum levels. Therefore, 
the caffeine blood levels should be carefully monitored only in 
neonates with low BW who have apnea or signs of toxicity. 
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